Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
Overview of attention for article published in Journal of Clinical Oncology, May 2018
Altmetric Badge
About this Attention Score
-
Above-average Attention Score compared to outputs of the same age (53rd percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 15 Mendeley